08:04 AM EDT, 10/03/2025 (MT Newswires) -- Ovid Therapeutics ( OVID ) said Friday that topline data from a phase 1 study of OV329 showed that the drug candidate achieved "statistically significant" inhibition of GABA-aminotransferase across multiple metrics.

The company said OV329 matched or exceeded inhibition demonstrated by therapeutic doses of vigabatrin, a first-generation drug.

Early data confirmed OV329 penetrated the brain and elevated mean GABA levels, supporting the drug candidate's intended mechanism of action, Ovid Therapeutics ( OVID ) said.

Safety and tolerability findings were favorable, with all treatment-related adverse events reported as mild and transient, according to the company.

Based on the results, Ovid Therapeutics ( OVID ) said it plans to advance OV329 into a phase 2a study in adult patients with drug-resistant focal onset seizures from Q2 2026.

Shares of Ovid were up more than 23% in recent Friday premarket activity.

Price: 2.05, Change: +0.39, Percent Change: +23.86